CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Death-Ligand 1 (PD-L1) Levels in KRAS-, KEAP1-, STK11-Mutant Lung Squamous Cell Carcinoma (LSCC)

Bridging Mammography and Lung Cancer Screening: Eligibility, Uptake and Potential Impact.

Cancer medicine·2026

SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026

Outcomes with frontline immune checkpoint inhibitors among individuals with BRAF-mutant non-small cell lung cancer.

Frontiers in oncology·2025

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.

Nature communications·2025

Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated Costs.

Clinical pharmacology and therapeutics·2025

Defining the needle in a haystack: A compendium of genomic, pathologic, and clinical characteristics of rare pulmonary tumors.

Lung cancer (Amsterdam, Netherlands)·2024

Fostering Improvements in Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

County-Level Medical Debt and Its Associations With Cancer Stage and Survival in the United States.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Current Surgical Perspectives for Pleural Mesothelioma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

NCCN Guidelines® Insights: Survivorship, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Metabolic Tumor Volume as a Predictor of Benefit From Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Delayed Diabetes Treatment and Persistent Hyperglycemia among Individuals with Schizophrenia: a Nationwide Register-Based Study.

Schizophrenia bulletin·2026

Evaluating Combined Sorafenib and Gemcitabine Treatment in HepG2 Cells and a NOD/SCID Mouse Xenograft Model: A Pilot Study.

Journal of visualized experiments : JoVE·2026

An Engineering-Editable Hybrid Membrane‑Camouflaged DNA Origami Drug Enables Checkpoint Blockade and Immune Activation for Triple-Negative Breast Cancer Immunotherapy.

Angewandte Chemie (International ed. in English)·2026

Chemotherapy-Activated GSK3β-DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Restoration of m6A-Modified circPSMB1 Suppresses Chordoma Progression and Enables Local Nanotherapeutic Intervention.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis.

Journal of food science·2026

Related Experiment Videos

CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Death-Ligand 1 (PD-L1) Levels in

Related Concept Videos

Bridging Mammography and Lung Cancer Screening: Eligibility, Uptake and Potential Impact.

SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer.

Outcomes with frontline immune checkpoint inhibitors among individuals with BRAF-mutant non-small cell lung cancer.

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.

Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated Costs.

Defining the needle in a haystack: A compendium of genomic, pathologic, and clinical characteristics of rare pulmonary tumors.

Fostering Improvements in Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

County-Level Medical Debt and Its Associations With Cancer Stage and Survival in the United States.

Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Current Surgical Perspectives for Pleural Mesothelioma.

NCCN Guidelines® Insights: Survivorship, Version 3.2026.

Metabolic Tumor Volume as a Predictor of Benefit From Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer.

Delayed Diabetes Treatment and Persistent Hyperglycemia among Individuals with Schizophrenia: a Nationwide Register-Based Study.

Evaluating Combined Sorafenib and Gemcitabine Treatment in HepG2 Cells and a NOD/SCID Mouse Xenograft Model: A Pilot Study.

An Engineering-Editable Hybrid Membrane‑Camouflaged DNA Origami Drug Enables Checkpoint Blockade and Immune Activation for Triple-Negative Breast Cancer Immunotherapy.

Chemotherapy-Activated GSK3β-DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma.

Restoration of m6A-Modified circPSMB1 Suppresses Chordoma Progression and Enables Local Nanotherapeutic Intervention.

Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis.

Related Experiment Videos

CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Death-Ligand 1 (PD-L1) Levels in...

Related Concept Videos

Related Articles

CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Death-Ligand 1 (PD-L1) Levels in